Anti-4-1bb nanobodies
US-2024383993-A1 · Nov 21, 2024 · US
against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K16/2878 |
| Official title | {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95} |
| Display label | against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 |
| Total patents | 3,075 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is stable.
| Year | Patents |
|---|---|
| 2015 | 108 |
| 2016 | 152 |
| 2017 | 167 |
| 2018 | 207 |
| 2019 | 265 |
| 2020 | 366 |
| 2021 | 343 |
| 2022 | 374 |
| 2023 | 354 |
| 2024 | 351 |
| 2025 | 316 |
| 2026 | 72 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
US-2024350630-A1 · Oct 24, 2024 · US
Anti-ox40 antibodies and uses thereof
US-2024352141-A1 · Oct 24, 2024 · US
Multiprotein-engineered cells secreting a multispecific antibody
US-2024344030-A1 · Oct 17, 2024 · US
Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
US-2024335536-A1 · Oct 10, 2024 · US
Anti-cd30l antibodies and uses thereof
US-2024254246-A1 · Aug 1, 2024 · US
Immunogenic fusion proteins against infectious animal diseases
US-2024141016-A1 · May 2, 2024 · US
Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
US-2024122984-A1 · Apr 18, 2024 · US
Antagonistic CD40 Monoclonal Antibodies and Uses Thereof
US-2024124597-A1 · Apr 18, 2024 · US
Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
US-11890303-B2 · Feb 6, 2024 · US
Method of producing a protein
US-2015368292-A1 · Dec 24, 2015 · US
Compositions comprising rank/rankl antagonists and related compounds for treating pain
US-2015359736-A1 · Dec 17, 2015 · US
Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
US-9211319-B2 · Dec 15, 2015 · US
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
US-2015352224-A1 · Dec 10, 2015 · US
Bcma antigen binding proteins
US-2015344583-A1 · Dec 3, 2015 · US
Fc variants with altered binding to FcRn
US-9200079-B2 · Dec 1, 2015 · US
Protein scaffolds
US-9176129-B2 · Nov 3, 2015 · US
Process for preparing stable antibody maytansinoid conjugates
US-2015306242-A1 · Oct 29, 2015 · US
Antibodies that bind human CD27 and uses thereof
US-9169325-B2 · Oct 27, 2015 · US
Anti-OX40 antibodies and methods of treating cancer
US-9163085-B2 · Oct 20, 2015 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K16/2878?
- CPC C07K16/2878 is the Cooperative Patent Classification code for “against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95.”
- How many patents are filed under CPC C07K16/2878 (against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95)?
- Our database includes 3,075 publications tagged with this CPC code.
- Is patent activity under CPC C07K16/2878 growing?
- Publication counts under this code: 351 in 2024 vs 316 in 2025 (latest complete years).